The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty
Open accessAbstract
BACKGROUND: Clinical trials and meta-analyses have suggested that aspirin may be effective for the prevention of venous thromboembolism (proximal deep-vein thrombosis or pulmonary embolism) after total hip or total knee arthroplasty, but comparisons with direct oral anticoagulants are lacking for prophylaxis beyond hospital discharge. METHODS: We performed a multicenter, double-blind, randomized, controlled trial involving patients who were undergoing total hip or knee arthroplasty. All the patients received once-daily oral rivaroxaban (10 mg) until postoperative day 5 and then were randomly assigned to continue rivaroxaban or switch to aspirin (81 mg daily) for an additional 9 days after total knee arthroplasty or for 30 days after total hip arthroplasty. Patients were followed for 90 days for symptomatic venous thromboembolism (the primary effectiveness outcome) and bleeding complications, including major or clinically relevant nonmajor bleeding (the primary safety outcome). RESULTS: A total of 3424 patients (1804 undergoing total hip arthroplasty and 1620 undergoing total knee arthroplasty) were enrolled in the trial. Venous thromboembolism occurred in 11 of 1707 patients (0.64%) in the aspirin group and in 12 of 1717 patients (0.70%) in the rivaroxaban group (difference, 0.06 percentage points; 95% confidence interval [CI], -0.55 to 0.66; P<0.001 for noninferiority and P=0.84 for superiority). Major bleeding complications occurred in 8 patients (0.47%) in the aspirin group and in 5 (0.29%) in the rivaroxaban group (difference, 0.18 percentage points; 95% CI, -0.65 to 0.29; P=0.42). Clinically important bleeding occurred in 22 patients (1.29%) in the aspirin group and in 17 (0.99%) in the rivaroxaban group (difference, 0.30 percentage points; 95% CI, -1.07 to 0.47; P=0.43). CONCLUSIONS: Among patients who received 5 days of rivaroxaban prophylaxis after total hip or total knee arthroplasty, extended prophylaxis with aspirin was not significantly different from rivaroxaban in the prevention of symptomatic venous thromboembolism. (Funded by the Canadian Institutes of Health Research; ClinicalTrials.gov number, NCT01720108 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Prevention of VTE in Orthopedic Surgery Patients
Falck-Ytter, Y., Francis, C. W., Johanson, N. A., Curley, C., Dahl, O. E., Schulman, S., Ortel, T. L., Pauker, S. G., & Colwell, C. W. (2012) · Chest · doi:10.1378/chest.11-2404 · Cited by 1,930
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
Lassen, M. R., Ageno, W., Borris, L. C., Lieberman, J. R., Rosencher, N., Bandel, T. J., Misselwitz, F., & Turpie, A. G. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa076016 · Cited by 1,295
(2000) · The Lancet · doi:10.1016/s0140-6736(00)02110-3 · Cited by 1,076
Kakkar, A. K., Brenner, B., Dahl, O. E., Eriksson, B. I., Mouret, P., Muntz, J., Soglian, A. G., Pap, Á. F., Misselwitz, F., & Haas, S. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60880-6 · Cited by 1,070
Turpie, A. G., Lassen, M. R., Davidson, B. L., Bauer, K. A., Gent, M., Kwong, L. M., Cushner, F. D., Lotke, P. A., Berkowitz, S. D., Bandel, T. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60734-0 · Cited by 981
Self-citationEikelboom, J. W., Quinlan, D. J., & Douketis, J. D. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05249-1 · Cited by 513
Goldhaber, S. Z. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16004-2 · Cited by 348
Cited by
Halvorsen, S., Mehilli, J., Cassese, S., Hall, T. S., Abdelhamid, M., Barbato, E., De Hert, S., de Laval, I., Geisler, T., Hinterbuchner, L., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac270 · Cited by 1,141
Khan, F., Tritschler, T., Kahn, S. R., & Rodger, M. A. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32658-1 · Cited by 753
Self-citationThe hypercoagulable state in COVID-19: Incidence, pathophysiology, and management
Abou-Ismail, M. Y., Diamond, A., Kapoor, S., Arafah, Y., & Nayak, L. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.06.029 · Cited by 694
Ferguson, R. J., Palmer, A. J., Taylor, A., Porter, M. L., Malchau, H., & Glyn-Jones, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31777-x · Cited by 634
Anderson, D. R., Morgano, G. P., Bennett, C., Dentali, F., Francis, C. W., Garcia, D. A., Kahn, S. R., Rahman, M., Rajasekhar, A., Rogers, F. B., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000975 · Cited by 626
Self-citation
Metadata
- Authors
- Anderson, D. R., Dunbar, M., Murnaghan, J., Kahn, S. R., Gross, P., Forsythe, M., Pelet, S., Fisher, W., Belzile, E., Dolan, S., Crowther, M., Bohm, E., MacDonald, S. J., Gofton, W., Kim, P., Zukor, D., Pleasance, S., Andreou, P., Doucette, S., Theriault, C., Abianui, A., Carrier, M., Kovacs, M. J., Rodger, M. A., Coyle, D., Wells, P. S., & Vendittoli, P.-A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02-22
- Volume
- 378
- Issue
- 8
- Pages
- 699-707
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2788601536
- Cited by
- 439
- References
- 17
- FWCI
- 43.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. https://app.cochat.ai/papers/10.1056/nejmoa1712746
- The paper
- Anderson, D. R., Dunbar, M., Murnaghan, J., Kahn, S. R., Gross, P., Forsythe, M., Pelet, S., Fisher, W., Belzile, E., Dolan, S., Crowther, M., Bohm, E., MacDonald, S. J., Gofton, W., Kim, P., Zukor, D., Pleasance, S., Andreou, P., Doucette, S., . . . Vendittoli, P.-A. (2018). Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1712746
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.